Lessons learned from an osteoporosis clinical trial in frail long-term care residents

• Published in: Clinical trials (London, England) England), 2012-04, Vol.9 (2), p.247-256
• Main Authors: Greenspan, SL, Nace, D, Perera, S, Ferchak, M, Fiorito, G, Medich, D, Zukowski, K, Adams, D, Lee, C, Saul, M, Resnick, NM
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - therapeutic use; Clinical trials; Diphosphonates - administration & dosage; Diphosphonates - therapeutic use; Drug therapy; Female; Frail Elderly; Frailty; Humans; Imidazoles - administration & dosage; Imidazoles - therapeutic use; Long term health care; Male; Osteoporosis; Osteoporosis - drug therapy; Patient Selection; Pennsylvania; Residential Facilities
• ISSN: 1740-7745; 1740-7753
• DOI: 10.1177/1740774511430516

Background Although osteoporosis affects women of all ages, the impact is most pronounced in frail residents in long-term care. Nevertheless, few interventional trials have been performed in this population, and few data on therapeutic alternatives are available in this cohort. Purpose We describe the challenges and lessons learned in developing and carrying out a trial in frail long-term-care residents. Methods The Zoledronic acid in frail Elders to STrengthen bone (ZEST) study was designed to examine the safety and efficacy of a single-dose therapy for osteoporosis in frail residents in long-term care in the Pittsburgh area. Women with osteoporosis who were 65 years of age and older and currently not on therapy were randomized in a blinded fashion to intravenous zoledronic acid or placebo. Follow-up of each participant was planned for 2 years. All participants received appropriate calcium and vitamin D supplementation. Results Seven hundred and thirty-three contacts were made with long-term care residents of nine participating facilities. Of 252 women screened, 181 were eligible, enrolled, and randomized. Multiple barriers to research in long-term-care facilities were encountered but overcome with direct communication, information sessions, in-service trainings, and social events. Lessons learned included designing the study in a manner that avoided placing an additional burden on an already overcommitted facility staff, a two-stage consent process to separate screening from randomization, and a flexible examination schedule to accommodate residents while obtaining the necessary outcome measurements. Furthermore, a mobile unit accessible to participants containing state-of-the-art dual x-ray absorptiometry (DXA), assessment for vertebral fractures, and phlebotomy equipment allows all assessments to be performed on-site at each facility. Serious adverse events are collected from affiliated hospitals in real time with a novel electronic surveillance system. Limitations The major limitation is selection of outcomes that can be assessed at participating facilities and do not require transport of participants to hospitals or clinics. Conclusions Clinical research for osteoporosis can be successfully and safely performed with frail residents in long-term care facilities. Lessons learned from this study may inform future investigations among frail elderly residents of these facilities.